HomePazopanibPazopanib + Pazopanib Hydrochloride

Does Pazopanib Interact with Pazopanib Hydrochloride?

Pazopanib and Pazopanib Hydrochloride have a major drug interaction according to U.S. FDA drug labeling data. 7 DRUG INTERACTIONS Strong CYP3A4 Inhibitors: Avoid coadministration of pazopanib tablets with strong CYP3A4 inhibitors. If coadministration cannot be avoided, reduce the dose of pazopanib tablets. Pazopanib tablets are not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This information is based on official FDA drug labeling sourced from OpenFDA and the NIH National Library of Medicine.

Severity
Major
Pazopanib Class
Kinase Inhibitor
Management
Close medical supervision required
Data Source
U.S. FDA via OpenFDA

What To Tell Your Doctor or Pharmacist

If you are taking Pazopanib and your doctor is considering prescribing Pazopanib Hydrochloride (or vice versa), make sure to:

  • Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
  • Ask whether the benefits of combining these medications outweigh the risks for your specific situation
  • Ask what symptoms to watch for that would indicate the interaction is causing problems
  • Ask how frequently you should be monitored while these are co-prescribed
  • Ask whether any dosage adjustments are needed
  • Never stop or change either medication without first consulting your healthcare provider
💊 Pazopanib+💊 Pazopanib Hydrochloride(Pazopanib)

Severity & Interaction Details

⚠️
major
Use with caution — major interaction
Serious risk of clinically significant harm. Generally avoid; if used, monitor closely.
Severity scale
MinorContra
On record
Yes
Drug A class
Kinase Inhibitor
Drug B class
Source
FDA drug label - pazopanib hydrochloride

What this means in plain English

7 DRUG INTERACTIONS Strong CYP3A4 Inhibitors: Avoid coadministration of pazopanib tablets with strong CYP3A4 inhibitors. If coadministration cannot be avoided, reduce the dose of pazopanib tablets. Pazopanib tablets are not recommended if chronic use of strong CYP3A4 inducers cannot be avoided.

Share this result:XFacebookWhatsAppReddit
Add more drugs
Check Pazopanib and Pazopanib Hydrochloride against your full medication list

Most patients take more than two medications. CDI checks every pair across up to 20 drugs simultaneously — including OTCs and common supplements.

Add more drugs →

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine. For informational purposes only. Always consult your pharmacist or physician.